Trending Now

Important medical research and remarkable case reports worth knowing.

Selected from high-relevance medical literature published in the last 14 days.

AllClinical ResearchCase Reports
FeaturedClinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

JAMASep 8, 2026Open access

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

Why it matters

The findings suggest that combining osimertinib with chemotherapy may enhance treatment outcomes for patients with specific genetic mutations in advanced NSCLC, potentially guiding personalized treatment strategies.

Read summary

Also worth knowing

Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchOncology (Medical)

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

The EMERALD-3 study evaluated the efficacy and safety of combining STRIDE (tremelimumab and durvalumab) with or without lenvatinib and transarterial chemoembolisation (TACE) in patients with embolisation-eligible…

Lancet OncolSep 1, 2026Read summary
Clinical ResearchOncology (Medical)

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

The HARMONi trial evaluated the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after progression on EGFR TKI…

Lancet OncolSep 1, 2026Read summary
Clinical ResearchUrology

PCa Detection in PI-RADS 4 and 5 Lesions: Comparison of [ 68 Ga]Ga-PSMA-11 PET/CT-Guided Robot-Assisted Biopsy Versus mpMRI Cognitive-Fusion TRUS-Guided Prostate Biopsy.

This randomized controlled trial compared the diagnostic performance of robotic arm-assisted [68Ga]Ga-PSMA-11 PET/CT-guided prostate biopsy (PGPB) with mpMRI-directed cognitive-fusion transrectal ultrasound-guided…

J Nucl MedSep 2, 2026Read summary
Clinical ResearchOncology (Medical)

First-Line PD-1 Inhibitor-Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta-Analysis of Phase III Trials.

This systematic review and meta-analysis evaluated phase III trials comparing first-line PD-1 inhibitor-based therapy to chemotherapy in advanced esophageal squamous cell carcinoma (ESCC).

Cancer Rep (Hoboken)Sep 1, 2026Read summary
Clinical ResearchGeneral Surgery

Impact of PerioperAtive LidocAine Infusions on Enhanced Recovery After Noncardiac Surgery (IMPALA-ERAS) in an inpatient setting: rationale, design and protocol for a sequential, repeated crossover trial.

The IMPALA-ERAS trial is a single-centre, pragmatic, cluster-randomised, double-blinded, placebo-controlled study evaluating the effects of perioperative intravenous lidocaine infusions on postoperative recovery in 2290…

BMJ OpenSep 8, 2026Read summary
Clinical ResearchOncology (Medical)

Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

This phase 1 multicenter trial evaluated arlocabtagene autoleucel (arlo-cel), a CAR T-cell therapy targeting GPRC5D, in 84 adults with heavily pretreated relapsed/refractory multiple myeloma.

BloodSep 3, 2026Read summary
Clinical ResearchOncology (Medical)

Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.

This phase III clinical trial evaluated the prognostic value of post-treatment circulating tumor DNA (ctDNA) detection in 313 patients with early-stage breast cancer.

JCO Precis OncolSep 4, 2026Read summary
Clinical ResearchOncology (Medical)

Validation of the newly introduced Deauville score 5a for patients treated for advanced-stage classic Hodgkin lymphoma.

This randomized controlled trial evaluated the prognostic value of the newly defined Deauville score 5a in patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) after two cycles of treatment.

Blood AdvSep 10, 2026Read summary
Clinical ResearchOncology (Medical)

A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).

The JCOG2314 trial is a multicenter, randomized phase II/III study evaluating tirabrutinib as a salvage treatment for refractory primary central nervous system lymphoma (PCNSL) compared to whole-brain radiotherapy…

Jpn J Clin OncolSep 9, 2026Read summary
Clinical ResearchOncology (Medical)

Cost-effectiveness analysis of a virtually administered pain coping skills training intervention in women with breast cancer in underserved areas.

This randomized controlled trial evaluated the cost-effectiveness of a virtual pain coping skills training (mPCST) intervention for women with breast cancer in underserved areas.

Palliat Support CareSep 9, 2026Read summary

Showing 12 of 174 publications that cleared our clinical screen in the last 14 days.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.